Multiple sclerosis: From basic immunopathology to immune intervention

Clinical Neurology and Neurosurgery

Volumn 104, Issue 3, 2002, Pages 172-176

  Miller, Ariel ^a   Galboiz, Yanina ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cytokines; Glatiramer acetate; Immunology; Pathogenesis; T cells

Indexed keywords

CYTOKINE; GLATIRAMER; IMMUNOGLOBULIN;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL ADHESION; CELLULAR IMMUNITY; CONFERENCE PAPER; DEMYELINATING DISEASE; DISEASE CLASSIFICATION; EMBRYO CELL; GRAY MATTER; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; LYMPHOCYTE MIGRATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PLASMAPHERESIS; STEM CELL; T LYMPHOCYTE;

ANTIBODY FORMATION; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CYTOKINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PLASMA EXCHANGE; T-LYMPHOCYTES;

EID: 0036071924     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(02)00034-3     Document Type: Article

References (39)

1. Interferon gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon beta therapy
2. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis
3. Treatment of multiple sclerosis with copolymer-1: implicating mechanisms of Th1 to Th2/Th3 immune-deviation
4. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
5. Antigen driven bystander suppression after oral administration of antigens
6. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase
7. Matrix metalloproteinases in immunity
8. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes
9. Matrix metalloproteinases: structure, evolution, and diversification
10. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic disease
11. Cytokine-regulated proteases in autoimmune diseases
12. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein
13. Matrix metalloproteinases degrade myelin basic protein
14. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of combined matrix metalloproteinase and tumour necrosis factor alpha inhibitor
15. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis
16. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions
17. The expression of tissue type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution
18. Metalloproteinaese and their tissue inhibitors in multiple sclerosis
19. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis
20. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients
21. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis
22. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
23. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors
24. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790
25. Reversal of experimental autoimmune encephalomyelitis with hydroxamate inhibitor of matrix metalloproteases
26. Apoptotic and effector pathways in autoimmunity
27. Oligodendrocyte apoptosis and primary demylination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy
28. Corticosteroids protect oligodendrocytes from cytokine-induced cell death
29. Defective T cell Fas function in patients with multiple sclerosis
30. Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis
31. New prospects for human stem-cell therapy in the nervous system
32. Heterogeneity of multiple sclerosis: implications for diagnosis and therapy
33. Antibody-mediated remyelination: relevance to multiple sclerosis
34. Is the routine use of intravenous immunoglobulin treatment in neurologic disorders justified
35. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating diseases
36. Axonal transection in the lesion of multiple sclerosis
37. Imaging axonal damage of normal- appearing white matter in multiple sclerosis
38. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients